Sarah E. Kleinstein, PhD

Post-Doctoral Fellow


skleinstein

You are here

Bio

Sarah Kleinstein joined the Department of Genomic Medicine at JCVI in December 2018. Working in Dr. Marcelo Freire’s lab, Dr. Kleinstein’s research is focused on host-microbial interactions and inflammation in chronic diseases, specifically investigating the role of chronic inflammation in type 2 diabetes.

Dr. Kleinstein received her PhD in molecular genetics and microbiology from Duke University. Prior to joining JCVI, she conducted research at the District of Columbia Public Health Laboratory Molecular Diagnostics Unit and at the Institute for Genomic Medicine at Columbia University. Dr. Kleinstein has a BS in biochemistry and an MS in genetic epidemiology, both from the University of Washington. Following her MS, she was a Centers for Disease Control and Prevention and Association for Public Health Laboratories Emerging Infectious Diseases Training Fellow at the California Department of Public Health Microbial Diseases Laboratory. Across her career, her research has focused on exploring the intersections of host-pathogen interactions, complex disease, and genetics.

Research Priorities

Chronic inflammation in type 2 diabetes

  • Neutrophil biology by transcriptomics
  • Resolution of inflammation therapeutics

Host-microbe interactions

  • Role of oral microbiome in chronic systemic diseases
  • Virulence factors influencing inflammation and chronic disease development

Genetics of complex traits

  • Investigating human neutrophil genetics in diabetes
  • Human genetics related to host-microbe interactions in chronic inflammatory diseases

Select Publications

Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2).
Genes and immunity. 2019-02-01; 20.2: 112-120.
PMID: 29535370
Whole-Exome Sequencing Study of Extreme Phenotypes of NAFLD.
Hepatology communications. 2018-09-05; 2.9: 1021-1029.
PMID: 30202817
Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018-06-01; 66.12: 1953-1956.
PMID: 29522085
Clinical application of whole-genome sequencing in patients with primary immunodeficiency.
The Journal of allergy and clinical immunology. 2015-08-01; 136.2: 476-9.e6.
PMID: 25981738
Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry.
Genes, chromosomes & cancer. 2014-07-01; 53.7: 568-78.
PMID: 24677636
An evaluation of copy number variation detection tools from whole-exome sequencing data.
Human mutation. 2014-07-01; 35.7: 899-907.
PMID: 24599517
COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.
Cancer causes & control : CCC. 2013-12-01; 24.12: 2059-75.
PMID: 24022467
Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.
Genes, chromosomes & cancer. 2013-05-01; 52.5: 437-49.
PMID: 23404351